DEF 14A: Pluri Inc. Announces Annual Shareholder Meeting to Elect Directors and Ratify Accounting Firm
Definitive Proxy Statement
Pluri Inc. will hold its annual shareholder meeting on June 25, 2024, to elect directors and ratify the selection of its independent accounting firm.
Summary
- Pluri Inc. will hold its annual meeting of shareholders on June 25, 2024, in Haifa, Israel, though remote communication is possible due to the ongoing war in Israel.
- Shareholders will vote to elect five directors to serve until the next annual meeting and to ratify the selection of Kesselman & Kesselman (PwC Israel) as the independent registered public accounting firm for the fiscal year ending June 30, 2024.
- The record date for determining shareholders eligible to vote is May 1, 2024.
- As of May 1, 2024, there were 5,388,792 common shares issued and outstanding, each entitled to one vote.
- The Board of Directors recommends voting for the election of each director nominee and for the ratification of the accounting firm selection.
- Shareholders can vote via internet, telephone, or by requesting and returning a paper proxy card.
Sentiment
Score: 6
Explanation: The document is primarily factual and procedural, related to the annual shareholder meeting. The mention of the war in Israel introduces a negative element, but overall the sentiment is neutral.
Positives
- The company is adhering to good corporate governance practices by submitting the selection of the independent auditors to the shareholders for ratification.
- The Board is actively monitoring the war in Israel and will announce alternative arrangements for the meeting if necessary.
Negatives
- The ongoing conflict in Israel may impact the company's operations and the ability to hold the annual meeting in person.
- The company's net loss decreased by 30%, from approximately $41,374,000 to $28,887,000.
Risks
- The war in Israel poses a risk to the company's operations and the ability to hold the annual meeting in person.
- The company faces risks related to strategic, operational, competitive, financial, legal, and regulatory matters.
- The company's insider trading policy prohibits directors and officers from engaging in certain transactions without prior written pre-clearance.
Future Outlook
The company is monitoring the war in Israel and may need to hold the annual meeting remotely. The Board believes that the current leadership structure provides an efficient and effective model for the Company to enable it to deliver better results and explore opportunities for the company and its investors.
Management Comments
- Mr. Aberman's transition to Chairman of the Board is intended to provide an efficient and effective leadership model.
- The Board believes that having different persons serving as Chairman and CEO, together with three independent directors is the optimal Board structure to provide independent oversight and management accountability while ensuring that our strategic plans are pursued to optimize long-term shareholder value.
Industry Context
Pluri Inc. operates in the biotechnology industry, which is subject to various risks including regulatory, financial, and operational risks. The company's focus on cell therapy and cultivated food solutions places it within the innovative segments of the life sciences industry.
Comparison to Industry Standards
- Executive compensation practices appear generally consistent with industry norms, with a mix of salary, bonus, and equity-based compensation.
- The company's audit fee structure is comparable to other publicly traded companies of similar size and complexity.
- The company's corporate governance practices, including the presence of independent directors and audit, compensation, and nominating committees, align with Nasdaq requirements and industry best practices.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Lorne Abony | N/A | June 25, 2024 | Mr. Abony has requested that he not be re-nominated as a director nominee. |
| Director | Varda Shalev | N/A | April 27, 2023 | Ms. Shalev and the Board mutually agreed that Ms. Shalev would not be re-nominated as a director nominee. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Amendment | Amendment to the compensation policy for non-executive officer directors, including annual cash compensation and additional fees for committee chairs and members. | January 23, 2024 | The amendment aims to align director compensation with their responsibilities and contributions to the company. |
Related Party Transactions
- Mr. Aberman's consulting agreement with the company, including fees and expense reimbursements.
- Compensation arrangements with executive officers, including salaries, bonuses, and equity-based compensation.
Stakeholder Impact
- Shareholders will have the opportunity to vote on key corporate governance matters.
- Executive compensation decisions may impact employee morale and retention.
- The company's financial performance and strategic decisions will affect shareholder value.
Next Steps
- Shareholders should vote on the director nominees and the ratification of the accounting firm.
- The company will hold its annual meeting on June 25, 2024.
- The company will continue to monitor the war in Israel and adjust meeting arrangements as necessary.
Key Dates
| Date | Description |
|---|---|
| September 12, 2018 | Date from which Mr. Yanay's employment agreement is in force for severance payment calculation. |
| September 10, 2020 | Date of grant of 62,500 RSUs to Mr. Yanay, linked to market capitalization target. |
| June 30, 2020 | Date from which Ms. Franco-Yehuda's employment agreement is in force for severance payment calculation. |
| January 1, 2021 | Start date of Mr. Yanay and Ms. Franco-Yehuda's salaries. |
| January 2022 | Zami Aberman became Chairman of the Board. |
| February 26, 2022 | Allocation of Ever After Foods shares to Mr. Yanay and Ms. Franco-Yehuda. |
| December 14, 2022 | Mr. Yanay agreed to forgo part of his salary in return for equity grants. |
| January 1, 2023 | Start date of Mr. Aberman's new consulting agreement. |
| February 13, 2023 | Board approved new arrangement of consulting fee of Mr. Aberman. |
| April 27, 2023 | Ms. Varda Shalev mutually agreed not to be re-nominated as a director. |
| June 30, 2023 | End of fiscal year 2023. |
| September 10, 2023 | Expiration date of RSUs granted on September 10, 2020, as market capitalization target was not met. |
| November 13, 2023 | Compensation Committee approved bonus payments to Mr. Yanay and Ms. Franco-Yehuda. |
| December 2023 | Board approved temporary salary/fee reductions due to the conflict in Israel. |
| January 23, 2024 | Board approved amendment to the compensation policy for non-executive officer directors. |
| April 1, 2024 | Reverse stock split implemented in the ratio of 8 to 1. |
| May 1, 2024 | Record date for the annual meeting. |
| May 9, 2024 | Mailing date of the Notice of Internet Availability of Proxy Materials. |
| June 25, 2024 | Date of the annual meeting of shareholders. |
| January 2, 2025 | Deadline for shareholder proposals for inclusion in the 2025 proxy statement. |
| March 17, 2025 | Deadline for shareholder proposals to be presented at the 2025 annual meeting without inclusion in the proxy materials. |
Keywords
annual meeting, proxy statement, directors, shareholders, Kesselman & Kesselman, accounting firm, corporate governance, executive compensation, Pluri Inc.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.